ChatGPT chatbot and similar technologies can either aid or exacerbate challenges the US faces in generating better evidence for patients to make informed health decisions, FDA Commissioner Robert M. Califf said.
“We’re great innovators, and we’re great at creating businesses. We’re failing to generate the evidence that’s needed to know which innovations are worth it and how to deploy them,” Califf said Thursday at the Health Datapalooza conference. “These new things, including ChatGPT and its friends, are disruptors that could be either positive or negative, depending on what we do with them.”
Califf has long bemoaned how the advances ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.